SOURCE: Paragon Financial Limited

Paragon Financial Limited

November 28, 2011 08:16 ET

Cheap Valuations in Viral Genetics and AEterna Zentaris Embraced by Investors

The Paragon Report Provides Equity Research on Viral Genetics & AEterna Zentaris

NEW YORK, NY--(Marketwire - Nov 28, 2011) - Despite disappointing third quarter results for some of biotechnology's up-and-coming stars, there is plenty of optimism in the industry. According to Lipper Inc. healthcare and biotechnology stock funds are up 17 percent this year and 35 percent over the past 12 months. Healthcare stocks underperformed during last year's market rally, and Andy Oh, research analyst and portfolio manager of the Fidelity Select Pharmaceuticals Fund argues that investors are embracing the "cheap valuations in health care stocks." The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Viral Genetics, Inc. (PINKSHEETS: VRAL) and AEterna Zentaris, Inc. (NASDAQ: AEZS) (TSX: AEZ). Access to the full company reports can be found at:

www.paragonreport.com/VRAL

www.paragonreport.com/AEZS

The increase in M&A activity in the healthcare sector is yet another reason investors are once again taking a close look at biotech stocks. Michael Gregory, portfolio manager of the Highland Long/Short Health care Fund argues that "acquisitions are needed to fuel growth" as government intervention suppresses growth in larger firms. Moreover, Big Pharma companies are about to face the largest patent expiration cliff in the industry's history and will need to fill the gap of lost income.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Cancer is projected to become the leading cause of death worldwide this year by the World Health Organisation, and has already emerged as the most expensive disease -- costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 million a year, it is clearly a lucrative sector for drug makers. AEterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. Aeterna said its AEZS-108 drug candidate, intended for the treatment of advanced endometrial cancer, achieved positive phase 2 results. The same drug, intended for the treatment of triple-negative breast cancer, earned an Investigational new drug approval from the US FDA and will enter phase 2 trials.

Viral Genetics, Inc., a biotechnology company, discovers and develops immune-based therapies for the treatment of HIV/AIDS and other infectious, autoimmune, and immunological deficiency disorders. Last week the company reported that a patent under which it is exclusively licensed will be granted for using a compound known as DCA to treat cancer. Viral Genetics says this "is the first patent granted for the use of DCA to treat cancer, and represents a significant milestone in the company's growth."

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer